Work

BAT8008, a TROP-2 antibody-drug conjugate (ADC), in patients with advanced solid tumor: Results from a phase 1 study.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.3024

Authors: Jianli Zhao, Xiao-Xiao Dinglin, Yongling Ji, Zhengbo Song, Yongsheng Li, Qing Wen, Meili Sun, Jinfeng Ma, Tienan Yi, Yanqiu Zhao, Wenjuan Chen, Hongrui Niu, Yunjian Huang, Hong Wang, Mingjun Zhang, Xiumin Li, Xingxiang Pu, Hailin Xiong, Hao Wang, Erwei Song

Institutions: Sun Yat-sen University, Sun Yat-sen Memorial Hospital, Zhejiang Cancer Hospital, Chongqing Cancer Hospital, Jinan Central Hospital, Shandong First Medical University, Shandong University, Shanxi Provincial Cancer Hospital, Xiangyang Central Hospital, Zhengzhou University, Henan Cancer Hospital, Fujian Medical University, Fujian Provincial Cancer Hospital, First Affiliated Hospital of Xinxiang Medical University, Third Hospital of Nanchang, Anhui Medical University, Second Affiliated Hospital of Anhui Medical University, Hunan Cancer Hospital, Huizhou Central People's Hospital

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410816480

Cites:

Cited by: 2

Related to: 10